Events And

EASL International Liver Congress™ 2023

Jun 23, 2023 at 8:30 AM CEST

Oral Presentation: OS-063 Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Presenter: Stephen A. Harrison, MD, Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University

Supporting Materials


Investor Contact

Richard Eisenstadt
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail